News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Amarin Corporation PLC (AMRN) Announces Notice of Allowance for Additional U.S. Patent Covering AMR101



7/2/2012 9:38:16 AM

BEDMINSTER, N.J., and DUBLIN, Ireland, July 2, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company focused on cardiovascular disease, announced today that the United States Patent and Trademark Office (USPTO) has published notification of a Notice of Allowance for U.S. Patent Application Serial Number 12/769,885 titled "Highly Stable EPA in a Capsule." A Notice of Allowance is issued after the USPTO makes a determination that a patent can be granted from an application. The issued patent would cover a stable pharmaceutical composition of AMR101 comprising at least 95% EPA and would have a patent term that would expire no earlier than in 2030.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES